{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T02:11:16Z","timestamp":1783649476310,"version":"3.55.0"},"reference-count":74,"publisher":"Wiley","issue":"23","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HER2\u2010targeted antibody\u2010drug conjugates (ADCs) have dramatically advanced breast cancer outcomes. Two HER2\u2010targeted ADCs, trastuzumab deruxtecan and trastuzumab emtansine, are currently approved for use in breast cancer, with &gt;\u200960 other candidates under ongoing investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this report, we provide a narrative review of existing data underlying the current understanding of HER2\u2010targeted ADC toxicities in breast cancer, highlighting both common and serious adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>When used as an adjuvant or neoadjuvant, first\u2010 or second\u2010line agent, alone or in combination with another agent, trastuzumab emtansine has been commonly associated with epistaxis, fatigue, headache, nausea, and pyrexia across several clinical trials. Comparatively, trastuzumab deruxtecan has been commonly associated with alopecia, cytopenias, decreased appetite, fatigue, and gastrointestinal adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite the demonstrated clinical benefits in breast cancer, diverse systemic and organ\u2010specific adverse events, including dose\u2010limiting toxicities, have been reported even at suboptimal therapeutic doses and pose significant barriers to pursuing dose escalations for maximizing therapeutic efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71415","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T05:30:43Z","timestamp":1765258243000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["HER2\u2010Targeted Antibody\u2010Drug Conjugate Toxicities in Breast Cancer"],"prefix":"10.1002","volume":"14","author":[{"given":"Seohyuk","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Section of Medical Oncology Yale University  New Haven Connecticut USA"},{"name":"Department of Medicine Beth Israel Deaconess Medical Center  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana M.","family":"Kahn","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Medical Oncology Yale University  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariya","family":"Rozenblit","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Medical Oncology Yale University  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mridula A.","family":"George","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute of New Jersey, Rutgers The State University of New Jersey  New Brunswick New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Naranjo Ortiz","sequence":"additional","affiliation":[{"name":"Yale Cancer Center Yale University  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-5645","authenticated-orcid":false,"given":"Maryam B.","family":"Lustberg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Section of Medical Oncology Yale University  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju055"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3798106"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13058\u2010021\u201001459\u2010y"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(19)30863\u20100"},{"key":"e_1_2_10_7_1","volume-title":"StatPearls Publishing","author":"Greenblatt K."},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000001932"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571\u2010021\u201000470\u20108"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010017\u201008151\u20102"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2016.02.008"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00457"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.04.008"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2022.10.016"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2016.1156829"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008\u20105472.CAN\u201015\u20101795"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201014\u20102093"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21705"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1248\/cpb.c18\u201000744"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201015\u20102822"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2017.07.013"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12966"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201011\u20100762"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101795"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(17)30312\u20101"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(17)30313\u20103"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814017"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32392"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00882"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.00896"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.Sabcs23\u2010gs01\u201010"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03398"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.14694\/EdBook_AM.2012.32.109"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598\u2010019\u201049251\u20105"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914510"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(23)00725\u20100"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115022"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA1000"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.Sabcs22\u2010gs2\u201003"},{"key":"e_1_2_10_41_1","doi-asserted-by":"crossref","unstructured":"C.Geyer \u201cTrastuzumab Deruxtecan (T\u2010DXd) vs Trastuzumab Emtansine (T\u2010DM1) in Patients (pts) With High\u2010Risk Human Epidermal Growth Factor Receptor 2\u2013Positive (HER2+) Primary Breast Cancer (BC) With Residual Invasive Disease After Neoadjuvant Therapy (tx): Interim Analysis of DESTINY\u2010Breast05 \u201d Presented At: ESMO Congress 2025; October 18 2025; Berlin Germany. Session Presidential Simposium I.","DOI":"10.1016\/j.annonc.2025.09.021"},{"key":"e_1_2_10_42_1","doi-asserted-by":"crossref","unstructured":"N.Harbeck \u201cDESTINY\u2010Breast11: Neoadjuvant Trastuzumab Deruxtecan Alone (T\u2010DXd) or Followed by Paclitaxel + Trastuzumab + Pertuzumab (T\u2010DXd\u2010THP) vs SOC for High\u2010risk HER2+ Early Breast Cancer (eBC) \u201d Presented At: ESMO Congress 2025; October 18 2025; Berlin Germany.","DOI":"10.1016\/j.annonc.2025.08.720"},{"key":"e_1_2_10_43_1","unstructured":"S.Tolaney \u201cResults From the DESTINY\u2010Breast09 trial: Trastuzumab Deruxtecan vs Trastuzumab Emtansine \u201d Presented at: ESMO Congress 2025; October 17 2025; Berlin Germany."},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.Sabcs23\u2010ps08\u201009"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad308"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/op.22.00480"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(19)30328\u20106"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.2088"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535\u20107163.Mct\u201019\u20101004"},{"key":"e_1_2_10_50_1","doi-asserted-by":"crossref","unstructured":"J.Zhang D.Ji W.Shen et\u00a0al. \u201cSafety and Anti\u2010Tumor Activity of ARX788 in HER2\u2010Positive Metastatic Breast Cancer Patients Whose Disease Is Resistant\/Refractory to HER2 Targeted Agents (Trastuzumab ADCs TKIs and Bispecific Antibodies): ACE\u2010Breast\u201001 Trial Results \u201d 2021.","DOI":"10.1158\/1538-7445.SABCS21-PD8-04"},{"key":"e_1_2_10_51_1","doi-asserted-by":"crossref","unstructured":"K.Jhaveri H.Han E.Dotan et\u00a0al. \u201cPreliminary Results From a Phase I Study Using the Bispecific Human Epidermal Growth Factor 2 (HER2)\u2010Targeting Antibody\u2010Drug Conjugate (ADC) Zanidatamab Zovodotin (ZW49) in Solid Cancers \u201d 2022.","DOI":"10.1016\/j.annonc.2022.07.589"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.10.183"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.1030"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.1028"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.1022"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.638482"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.Sabcs20\u2010pd1\u201009"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.1002"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3646"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3153"},{"key":"e_1_2_10_61_1","doi-asserted-by":"crossref","unstructured":"E.Hamilton A.Chaudhry A.Spira et\u00a0al. \u201cA Phase 1b Trial of a B7\u2010H4 Targeted Antibody Drug Conjugate (ADC) in Breast Endometrial and Ovarian Cancers \u201d 2022.","DOI":"10.1016\/j.ygyno.2023.06.159"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.141"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201020\u20104740"},{"key":"e_1_2_10_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS1127"},{"key":"e_1_2_10_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS1104"},{"key":"e_1_2_10_66_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.Sabcs18\u2010ot2\u201006\u201004"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538\u20107445.Sabcs19\u2010pd1\u201006"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.150"},{"key":"e_1_2_10_69_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122898"},{"key":"e_1_2_10_70_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.753491"},{"key":"e_1_2_10_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.12.008"},{"key":"e_1_2_10_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_281107"},{"key":"e_1_2_10_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/protein\/gzw054"},{"key":"e_1_2_10_74_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045\u2010021\u201001035\u2010z"},{"key":"e_1_2_10_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.3087"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71415","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71415","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71415","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:27:07Z","timestamp":1771331227000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":74,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/cam4.71415"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71415","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-01-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71415"}}